Tumor Ablation Market

Market Definition

Global Tumor Ablation Market was valued at USD 652.2 million in 2020 and is set to grow at a CAGR of 11.6% from 2021 to 2027.

Tumor ablation is a minimally invasive procedure that is commonly used in the treatment of tumors such as liver, kidney, bone, and lung. Ablation is a needle-based treatment that destroys cancerous or abnormal tissue.

Market Dynamics

Rising incidence of cancer is the major factor boosting the growth of the market. For instance, according to the American Cancer Society, in 2020 there were 191,930 new cases of prostate cancer and 33,330 deaths from prostate cancer in the United States. According to the World Health Organization (WHO), globally, lung cancer accounts for 2.09 million cases in 2018. According to the American Cancer Society, in 2020, around 228,820 new cases of lung cancer was diagnosed in the United States. According to the World Health Organization (WHO), globally, colorectal cancer accounts for 1.80 million cases in 2018. According to the American Cancer Society's (ACS), in 2020, around 147,950 adults in the United States are diagnosed with colorectal cancer. According to the American Institute for Cancer Research, breast cancer is the second most common cancer globally. Globally, around 2 million new cases of breast cancer are diagnosed in 2018. Around 627,000 women died from breast cancer, which is approximately 15% of all cancer deaths among women in 2018. Further, rising demand of minimally invasive surgeries is a key driving factor of the market. However, side effect of tumor ablation might hamper the market growth. The side effects of ablation therapy include abdominal pain, infection in the liver, fever and abnormal liver tests. There can be serious complications which are uncommon, but they are possible. Moreover, growing awareness about ablation procedures over conventional therapeutic and surgical procedures would provide lucrative opportunities for the market in coming years.

Market Segmentation

The global tumor ablation market is mainly classified based on technology, mode of treatment, and application. Technology is further segmented into Radiofrequency, Cryoablation, Microwave, IRE, Ultrasound, and Laser. By mode of treatment the market is divided into Laparoscopic, Surgical, and Percutaneous.

Radiofrequency segment is valued at USD 808.7 million in 2026 and is projected to reach USD 1751.7 million by 2033, at a CAGR of 11.7% during the forecast period.

By application the market is further divided into Lung, Kidney, Liver, Breast, Bone Metastasis, and Prostate.

Lung segment is projected to reach USD 1278.5 million by 2033.

Based on technology, the radiofrequency ablation accounted for the largest share in 2020, attributed to its proven clinical efficacy and safety profile, ease of treatment, the development & commercialization of technologically advanced radiofrequency tumor ablation systems, and increasing regulatory approval of radiofrequency tumor ablation systems. For instance, Medtronic plc has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Accurian RF ablation platform, which conducts radio frequency (RF) ablation of nerve tissues. RF ablation is a minimally invasive procedure in which current produced by radio waves heats up a small area of nerve tissue to stop it from sending pain signals, thereby reducing pain. The Accurian system offers independent channel management and advanced smart features that may support procedural efficiency.

Regional Analysis

Based on geography, the global tumor ablation market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America was dominating the tumor ablation market in 2020, owing to the high prevalence and incidence of cancer, rising adoption of minimally invasive procedures by patients for cancer treatment, increasing government funding for cancer research, and collaboration between companies to develop and commercialize tumor ablation system. For instance, Auris Health, Inc. has entered into a cooperative development and commercialization agreement with NeuWave Medical, Inc., a subsidiary of Ethicon, Inc., with the goal of enabling robotically assisted bronchoscopic ablation of lesions in the lung.

Competitive landscape

Key players operating in the tumor ablation industry include Boston Scientific Corporation, Medtronic, Plc, Angiodynamics, Inc., Misonix Inc., EDAP TMS S.A, HealthTronics, Johnson and Johnson, Mermaid Medical, Inc., Chongqing Haifu Medical Technology Co., Ltd., and SonaCare Medical, LLC.

Commercialization of tumor ablation system by the companies, partnerships between companies to develop tumor ablation system, mergers and acquisitions by the market players to sustain their position in the market, companies are investing in R&D to develop minimally invasive and innovative tumor ablative system, and increasing research studies on tumor ablation system. For instance, on December 15, 2020, Medtronic plc has conducted first 100 patients treatment with the OsteoCool Radiofrequency Ablation (RFA) System in the OPuS One Clinical Study. The study on OsteoCool technology showed patients had significant and swift improvement in pain relief at just three days post-procedure and sustained improvements in pain and quality of life out to six months.

Tumor Ablation Market Key Segments:

By Technology

• Radiofrequency
• Cryoablation
• Microwave
• IRE
• Ultrasound
• Laser

By Mode of Treatment

• Laparoscopic
• Surgical
• Percutaneous

By Application

• Lung
• Kidney
• Liver
• Breast
• Bone Metastasis
• Prostate

Key Global Tumor Ablation Industry Players

• Boston Scientific Corporation
• Medtronic, Plc
• Angiodynamics, Inc.
• Misonix Inc.
• EDAP TMS S.A
• HealthTronics
• Johnson and Johnson
• Mermaid Medical, Inc.
• Chongqing Haifu Medical Technology Co., Ltd.
• SonaCare Medical, LLC

What Report Provides

• Key Company Market Share, Revenue, and Position/Ranking
• Key Market Leaders
• Full In-Depth Analysis of the Parent Industry
• Industry Statistics
• Important Changes in Market and Its Dynamics
• Segmentation Details of the Market
• Historical, On-Going, and Projected Market Analysis
• Assessment of Niche Industry Developments
• Market Share Analysis
• Key Strategies of Major Players
• Company Profiles of Key Players
• Unique Selling Prepositions of Leading Market Players
• Emerging Segments and Regional Growth Potential
• Key Strategic Recommendations
• Competitive Benchmarking
• Import Export Trade Statistics